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A Src SH2 selective binding compound inhibits osteoclast-
mediated resorption
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Background: The observations that Src–/– mice develop osteopetrosis and Src
family tyrosine kinase inhibitors decrease osteoclast-mediated resorption of
bone have implicated Src in the regulation of osteoclast-resorptive activity. We
have designed and synthesized a compound, AP22161, that binds selectively
to the Src SH2 domain and demonstrated that it inhibits Src-dependent cellular
activity and inhibits osteoclast-mediated resorption. 
Results: AP22161 was designed to bind selectively to the Src SH2 domain by
targeting a cysteine residue within the highly conserved phosphotyrosine-
binding pocket. AP22161 was tested in vitro for binding to SH2 domains and
was found to bind selectively and with high affinity to the Src SH2 domain.
AP22161 was further tested in mechanism-based cellular assays and found to
block Src SH2 binding to peptide ligands, inhibit Src-dependent cellular activity
and diminish osteoclast resorptive activity.
Conclusions: These results indicate that a compound that selectively inhibits
Src SH2 binding can be used to inhibit osteoclast resorption. Furthermore,
AP22161 has the potential to be further developed for treating osteoporosis.
Introduction
The Src family of tyrosine kinases (Src, Fyn, Yes, Yrk,
Lyn, Hck, Fgr, Blk, Lck, Frk/Rak and Iyk/Bsk) plays an
important role in regulating intracellular signaling events.
Their physiological importance is relative to the cell type
in which they reside, their level of expression, and the
upstream signaling events that lead to their activation (for
reviews see [1,2]). The Src tyrosine kinases contain
several conserved domains including a unique myris-
toylated amino-terminal domain, an SH2 domain, an SH3
domain, a catalytic kinase domain and a negative regula-
tory carboxyl tail [1–3]. Although the catalytic kinase
domain is important for autophosphorylation and down-
stream phosphorylation of protein substrates, the SH2
domain has been postulated to play an important role in
regulating intracellular signaling events by acting as an
adaptor that brings specific protein substrates into the sig-
naling complex and as a determinant of Src tyrosine
kinase subcellular localization [4,5]. The physiological
function(s) of many Src tyrosine kinases have been eluci-
dated from mice in which a specific tyrosine kinase gene
has been disrupted or eliminated using gene targeting
technology [6]. These studies have provided information
regarding the potential effect(s) of compounds that block
the activity of a particular tyrosine kinase protein. Studies
with Src–/– mice, in which the major phenotype is
osteopetrosis (overly thick bones), have indicated that Src
plays an important function in regulating osteoclast-medi-
ated resorption of bone [7–9]. Src is normally expressed at
high levels as a membrane-associated protein in osteo-
clasts [10,11], and Src–/– osteoclasts do not form an orga-
nized actin cytoskeleton or a membrane-associated
ruffled border, and do not produce the lacunae that are
necessary for proper resorption of bone [7–9,12]. The
defect in bone homeostasis in Src–/– mice therefore
appears to be linked to the regulation of osteoclast adhe-
sion and subsequent signaling events that are integrated
into the resorption process. A compound that blocks
specifically the function of Src should inhibit osteoclast-
mediated resorption of bone and have a potential role in
the treatment of osteoporosis. Src family kinase
inhibitors, both in vitro and in vivo, have been found to
inhibit osteoclast-mediated resorption of bone [13–16].
Because these compounds are not specific for the Src
kinase domain (they also inhibit other Src kinase family
members), studies with these compounds do not demon-
strate that the effects are the result of inhibiting any one
Src family tyrosine kinase protein.
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A major challenge in developing small-molecule inhibitors
specific for the Src tyrosine kinase is designing a com-
pound that selectively binds to one member of the family.
This is particularly true when targeting the SH2 domain,
which is highly conserved within this family of proteins
[17–19]. In a separate report we will describe bone
binding as a means to target selectively Src family SH2
inhibitors to osteoclasts (S.M.V., et al., unpublished obser-
vations). In this paper we describe using a biochemical
approach to target the Src SH2 domain. Unique to Src
among this family of protein tyrosine kinases is the pres-
ence of a cysteine residue (Cys188) in the phosphotyro-
sine-binding pocket of its SH2 domain. We and others
[20–22] have investigated the importance of this cysteine
residue in the design of pTyr mimics. Modeling predicted
the thiol moiety of the cysteine residue of Src SH2 might
impart biochemical selectivity. Src is the only member of
the family to contain this residue (all others possess serine
or threonine). Precedent for this type of interaction comes
from the previously reported design and synthesis of
reversible, high-affinity ligands for cysteine proteases in
which the active site contains a reactive thiol [23–26].
Although it is unlikely that the thiol of Cys188 is fully
ionized, the concentration of positively charged residues
in the pocket is likely to decrease the pKa and increase its
reactivity. In support of this, it has been determined that
the pKa of His57 and pTyr, in a PLC-γ1 SH2 domain–
pY1021 complex, are significantly reduced because of the
proximity of these groups to the highly charged pTyr
binding pocket [27]. The cysteine residue in the Src SH2
domain may therefore be more reactive than cysteine
residues in general and in the context of the SH2-binding
pocket provides a potential site for designing a compound
that binds with selectivity. As an important note, an
elegant biochemical approach has been previously
described for the design and synthesis of selective and
potent inhibitors of the Grb2 SH2 domain [28]. Here we
describe the synthesis of a cysteine-targeted compound
that selectively binds to the Src SH2 domain with
nanomolar binding affinity. We also demonstrate that
this compound blocks Src SH2 binding to peptide
ligands in cells, decreases Src-dependent cellular activity
and inhibits osteoclast-mediated resorption.
Results
Inhibition of Src SH2-ligand binding
AP22161 was designed and synthesized as a compound
that would selectively bind to the Src SH2 domain and
inhibit binding to its peptide ligand (Figure 1). AP22161
was designed to target binding to the cysteine residue in
the phosphotyrosine-binding pocket of the Src SH2
domain. A fluorescence-polarization-based competitive
binding assay was utilized to determine the IC50 of
AP22161 and control peptides binding to the Src SH2
domain, the Yes SH2 domain and the tandem ZAP SH2
domains [29]. The binding assay was therefore used to
monitor both relative binding affinity and selectivity of
binding. AP22161 was assayed for its ability to inhibit Src,
Yes and ZAP SH2 domains binding to fluorescein-conju-
gated peptide ligands. The Yes SH2 domain (Figure 2) was
chosen from the Src family of tyrosine kinase proteins for
comparison with the Src SH2 domain because it is the most
structurally related to the Src SH2 domain [18,30]. The
ZAP tyrosine kinase protein was included in the binding
assay because it contains structurally distant SH2 domains
and confirms binding specificity. pYEEI, a known Src SH2
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Figure 1
Chemical synthesis scheme and structure of
AP22161. (a) Chemical structure of
AP22161. (b) Synthesis scheme.
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ligand [1,31], which served as a positive control for compar-
ison with AP22161, inhibited Src SH2 binding to the fluo-
rescein-conjugated ligand with an IC50 of 5.5 µM
(Table 1). The native ZAP SH2 domain ligand, ζ-1-ITAM
(NQLpYNELNLGRREEpYDVLD, using single-letter
amino-acid code where pY is phosphotyrosine), found in
the cytoplasmic domain of the CD3 receptor, also served as
a positive control and inhibited Src SH2 binding with an
IC50 of 11.07 µM. By comparison, AP22161 had a signifi-
cantly lower IC50 of 0.24 µM in the Src SH2 binding assay
(Table 1 and Figure 3). In addition, AP22161 had selectiv-
ity for binding to the Src SH2 domain because it had a
100-fold higher IC50 for blocking the binding of the same
fluorescein-conjugated peptide to the structurally related
Yes SH2 domain. The positive control peptide, pYEEI,
had a similar IC50 value in the Src SH2 and Yes SH2
binding assays. As expected, AP22161 did not inhibit the
binding of the fluorescein-conjugated peptide ligand to the
tandem ZAP SH2 domains. AP22161 was therefore identi-
fied as a compound that demonstrated high affinity and
selective binding to the Src SH2 domain. 
Mammalian two-hybrid assay
Given that AP22161 showed high-affinity binding to the
Src SH2 domain in vitro we wanted to demonstrate further
that it inhibited Src SH2 binding to peptide ligands in
cells. The mammalian-cell-based two-hybrid assay pro-
vided a model to evaluate whether compounds permeate
cells, demonstrate inhibition of Src SH2 binding to peptide
ligands, and elicit any signs of cellular toxicity [32]. Cells
were engineered to contain an SH2 domain transcriptional
activation domain fusion protein and an SH2 peptide
ligand–GAL4 DNA binding domain–estrogen receptor
ligand binding domain–Src kinase fusion protein
(Figure 4). Compounds were screened in two different Src
SH2 cell lines (Src-SH2/IgE-β and Src-SH2/ζ-ITAM), a
negative control GerVP cell line and a ZAP SH2 cell line.
Details of these two-hybrid cell lines have been described
previously [32]. The Src SH2 cell lines express the
secreted alkaline phosphatase (SEAP) reporter gene under
the control of a Src SH2 ligand-binding interaction. Both of
the Src SH2 cell lines contain the same Src SH2 domain
construct, but each express different ligand-binding pep-
tides. Compounds that inhibit binding to the Src SH2
domain would be expected to inhibit SEAP expression in
both of these cell lines. The ZAP SH2 cell line expresses
SEAP under the control of a ZAP SH2 ligand-binding
interaction, whereas the GerVP negative control cell line
expresses the SEAP reporter gene independent of an
SH2–ligand interaction. Both the GerVP and the ZAP two-
hybrid cells serve as negative controls to determine
whether compounds selectively inhibit Src SH2-ligand
binding. The ZAP cell line, containing a structurally
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Figure 2
Sequence comparison of human Src, Yes and
ZAP SH2 domains. Residues that correspond
to Cys188 in the Src SH2 domain are bold
and underlined.
Table 1
Inhibition of Src, Yes and ZAP SH2 domains binding to peptide
ligands in vitro.
Src SH2 IC50 Yes SH2 IC50 ZAP SH2 IC50
(µM) (µM) (µM)
AP22161 0.24 ± 0.04 29.38 ± 3.60 421.86 ± 47.69
pYEEI 5.56 ± 0.21 4.26 ± 0.25 530.12 ± 49.02
ζ-ITAM peptide* 11.07 ± 0.09 23.63 ± 1.19 0.05 ± 0.01
*ζ-1-ITAM peptide = Ac-NQLpYNELNLGRREEpYDVLD-NH2 and
pY = (H2O3PO)-Tyr. AP22161 and control peptides were assayed for
their ability to inhibit Src, Yes and tandem ZAP SH2 domains binding
to a fluorescein-conjugated peptide ligand. Results are shown as mean
IC50 values (µM) ± S.E.M.
Figure 3
Inhibition of Src SH2 binding to peptide ligand by AP22161.
Increasing concentrations of AP22161 were assayed for inhibition of
Src SH2 domain binding to a fluorescein-conjugated peptide. Data are
shown as the mean % inhibition of binding ± S.E.M.
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distant related SH2 domain, monitors for nonspecific SH2-
binding interactions. The GerVP and ZAP cell lines are
also used to monitor nonspecific inhibition of SEAP pro-
duction as a result of toxicity. All the cell lines described
express SEAP in an estrogen-inducible manner. Cells were
incubated for 16 hours with AP22161 and estrogen, and
SEAP activity was examined. Cellular toxicity was also
monitored by alamar activity and [3H]-uridine incorpora-
tion. AP22161 selectively inhibited SEAP production from
both of the Src SH2 two-hybrid cell lines (Figure 5a) with
an IC50 of 60.0 µM in the Src SH2 ζ cell line and an IC50 of
80.1 µM the Src SH2 IgE-β cell line. In the negative
control cell lines, AP22161 had minimal effects on estro-
gen-induced SEAP production. AP22161 did not induce
any significant toxicity at any concentration as monitored
by alamar reactivity (Figure 5b) or [3H]-uridine incorpora-
tion (data not shown). The inhibition curve observed for
AP22161 in the Src SH2 two-hybrid cell assay was steeper
than that in the fluorescence polarization binding assay. In
the two-hybrid assay there was ~80% inhibition across
one log concentration of AP22161, whereas in the fluo-
rescence polarization binding assay the same extent of
inhibition was observed across a two log concencentra-
tion of AP22161. The fluorescence polarization inhibi-
tion curve fits the expected model that given one
binding site, there should be approximately a two log dif-
ference in the inhibitor concentration going from 10 to
90% occupancy. In contrast, in the two-hybrid assay, the
expression of the reporter gene, under the control of
multiple DNA-binding events and five tandem Gal4-
binding sites upstream of the reporter gene [32], is
expected to introduce cooperative binding and thus a
steeper curve of inhibition.
Effect of compounds on the morphology and growth of
cSrcY527F transformed cells
Activated Src is a potent inducer of cellular transfomation,
resulting in altered growth and morphology of cells [3].
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Figure 4
The mammalian two-hybrid cell assay. Cells
contain an integrated secreted alkaline
phosphatase (SEAP) reporter gene under the
control of a GAL4-responsive promoter. Cells
used to monitor SH2 domain-dependent
binding were engineered to constitutively
express a GAL4 DNA binding
domain–estrogen receptor (ER)
ligand-binding domain–Src kinase domain–
SH2 domain ligand fusion protein; and a
transcriptional activation domain–SH2 domain
fusion protein. SH2 domain–peptide ligand
interactions are observed when cells are
exposed to estrogen. (a) Binding of the two-
hybrid constructs within cells resulting in
reporter gene expression. (b) Binding of
compounds to the Src SH2 domain
preventing activation domain binding and
subsequent reporter gene expression. (c) The
negative control GerVP cell line (containing a
constitutively expressed GAL4 DNA binding
domain–estrogen receptor ligand-binding
domain–VP16 transcriptional activation
domain fusion protein) where reporter gene
expression is independent of an SH2-ligand
binding interaction. Details of two-hybrid cell
lines have been previously described [32].
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Thus, cells transformed with an activated form of Src could
serve as a cellular system to assay compounds for inhibition
of Src activity. AP22161 was examined for its ability to
revert the morphology and inhibit the growth of rat fibro-
blasts transformed with mutant cSrcY527F as a means to
monitor repression of Src cellular activity. In this mutant
version of Src, the tyrosine kinase remains in an open con-
formation, and the kinase is constitutively active.
cSrcY527F transformed cells appear rounded as they reach
confluence and show loss of contact inhibition of growth
[33], whereas the parent fibroblasts grow to form a conflu-
ent monolayer (Figure 6). The Src family kinase inhibitor
PP1 was also tested as a known blocker of Src activity [34].
PP1 induced a concentration-dependent reversion of the
morphological phenotype with complete reversion
observed at 5 µM (Figure 6). PP1 also inhibited the growth
of cSrcY527F transformed cells 74.5% after 5 days of treat-
ment with 1.5 µM compound (Figure 7). The Src SH2
domain inhibitor AP22161 showed partial morphological
reversion of the transformed phenotype at 100 µM. The
effect of AP22161 on the morphology of the cSrcY527F
cells was similar to that observed with 0.5 µM PP1. 100 µM
AP22161 inhibited the growth of the cSrcY527F cSrc cells
26.3 % after 5 days of exposure (Figure 7). Given the IC50
of AP22161 in the Src two-hybrid assay of 60–80 µM, we
would expect an IC50 in the reversion assay to be in a
similar range or higher. Although not as potent as the
kinase inhibitor PP1, AP22161 demonstrated the ability to
inhibit Src functional activity in cSrcY527F transformed
cells. The difference in potency could be related to a
number of factors including mechanism of action, cellular
permeability and compound stability. 
Effect of AP22161 on rabbit osteoclast resorption
Because Src has been implicated in the regulation of
osteoclast functional activity, AP22161 was examined for
its ability to inhibit osteoclast-mediated resorption of
dentine. AP22161 was tested at concentrations in the
range of 1.2–100 µM. AP22161 inhibited resorption of
dentine with an IC50 of 42.92 µM (Table 2). AP22161 did
not demonstrate signs of toxicity at any of the concentra-
tions tested as monitored by the presence of tartrate resis-
tant acid phosphatase (TRAP)-positive cells and
surrounding fibroblasts. These findings indicate that a
compound that binds selectively to the Src SH2 domain,
and inhibits Src binding to ligand in cells, can inhibit
osteoclast-mediated resorptive activity. PP1 was also
tested as a control compound and found to have an IC50 of
1.18 µM. This is consistent with its activity on the rever-
sion of morphology and inhibition of growth of cSrcY527F
transformed cells.
On the basis of its IC50 in the two-hybrid assay, we
expected AP22161 to have an IC50 in the high micromolar
range in the SrcY527F transformed cell assay and in the
osteoclast-resorption assay. Although AP22161 has an IC50
of 0.24 µM in the fluorescence polarization binding assay,
the aldehyde moiety of the pTyr mimic or AP2216 may
not be chemically or metabolically stable. We have also
determined that structurally similar compounds without
the aldehyde have a 100-fold higher IC50 in the fluores-
cence polarization binding assay (W.C.S., unpublished
observations). If the intracellular concentration of the
active species is in fact in the high micromolar range we
may expect inhibition of other Src SH2 family members
such as Yes. If AP22161 were nonspecifically inhibiting
other Src SH2 family members we would expect to see
nonspecific signs of toxicity, such as decreased transcrip-
tion and alamar reactivity in the two-hybrid cells or
decreased numbers of fibroblasts and TRAP staining
osteoclasts in the resorption assay. These types of effects
have been observed with compounds that nonspecifically
inhibit Src family kinases, as also seen with concentrations
of PP1 > 2 µM. Rather, we believe that AP22161 may be
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Figure 5
Inhibition of Src SH2 domain binding to ligands in mammalian
two-hybrid cells. AP22161 was tested at increasing concentrations for
(a) its effects on the production of SEAP and (b) alamar reactivity in
Src-SH2/IgE-β (open circles), Src-SH2/ζ ITAM (closed circles),
GerVP (open squares) and ZAP (closed squares) two-hybrid cells.
Data are shown as mean % of control ± S.E.M. SEAP production and
alamar reactivity relative to vehicle alone treated cells.
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less stable intracellularly and that the extracellular concen-
tration is not a true indication of the intracellular concen-
tration. It is also noted that there was a structure–activity
relationship for the 3-formyl-4-carboxy-substituted-
phenyalanine-containing compounds when comparing
in vitro binding data with two-hybrid assay data. Com-
pounds ranked similarly comparing the two assays. In
addition, only compounds that had an IC50 less than 1 µM
in the binding assay showed significant inhibition of osteo-
clast-mediated resorption at concentrations ≤ 200 µM.
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Figure 6
Morphological reversion of cSrcY527F
transformed rat fibroblasts. cSrcY527F
transformed rat fibroblasts were incubated
with vehicle alone, 0.5 µM PP1, 1.5 µM PP1,
5 µM PP1 or 100 µM AP22161 for 4 days.
Parent F1-11 rat fibroblasts are shown as the
untransformed matched control cells. Cells
were examined using light microscopy and
compared with vehicle alone treated
cSrcY527F and F1-11 rat fibroblasts.
(a) Cells are shown at 10× magnification.
(b) Cells are shown at 20× magnification.
Figure 7
Growth inhibition of cSrcY527F transformed rat fibroblasts.
cSrcY527F rat fibroblasts were cultured for 2, 3, 4, 5 and 7 days with
vehicle alone (open circles), 100 µM AP22161 (closed circles), or
1.5 µM PP1 (open squares). Data are shown as the mean number of
cells counted ± S.D.
Table 2
Inhibition of rabbit osteoclast-mediated resorption of dentine.
AP22161 concentration (µM) % Inhibition
1.23 26.86 ± 8.05
3.7 26.05 ± 7.68
11.1 34.66 ± 3.25
33.3 42.53 ± 12.14
100 67.65 ± 12.09
IC50 = 42.92 µM
PP1 concentration (µM) % Inhibition
25 99.37 ± 0.61
5 96.93 ± 2.85
1 44.63 ± 27.56
0.2 17.14 ± 28.61
0.04 0 ± 18.92
IC50 = 1.18 µM
AP22161 and PP1 were assayed at increasing concentrations.
Percent inhibition of resorption and IC50 values were calculated on the
basis of three separate experiments containing triplicate samples for
each concentration tested.
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Discussion
Although Src has been implicated in regulating osteoclast-
mediated resorption of bone, there has been little evi-
dence that selective inhibition of Src activity using
pharmacological approaches would result in inhibition of
osteoclast-resorptive activity. In addition, Src contains
many different regulatory domains. One of these domains,
the SH2-ligand-binding domain, is known to regulate the
activation state of Src and its ability to mediate intracellu-
lar signaling. There has been little information to indicate
that inhibition of Src SH2 binding to its cognate ligand
will diminish its cellular activity, however. Most informa-
tion regarding the effects of inhibiting Src protein tyrosine
kinases in osteoclasts has come from studying the effects
of tyrosine kinase inhibitors on osteoclast resorption and
genetic targeting of the Src gene in mice. Src family tyro-
sine kinase inhibitors have been found to inhibit osteo-
clast function in both in vitro and in vivo models of bone
resorption [13–16]. Because the compounds tested do not
selectively inhibit Src, however, it is not clear whether the
effects observed are a result of inhibiting more than one
member of the Src kinase family. They also do not address
whether inhibition could be attained by inhibiting SH2
domain binding to ligand. The observation that osteoclasts
in Src–/– mice are not able to resorb bone indicates that
selective inhibition of Src function should also lead to
inhibition of osteoclast resorption. Transgenic mouse
approaches to rescue Src function in Src–/– mice have pro-
vided some information regarding the role that individual
domains may play in osteoclast-mediated resorption of
bone. Genetic rescue experiments in which physiological
levels of a kinase-dead mutant were expressed in osteo-
clasts of Src–/– mice have suggested that the kinase domain
may not be a key regulator of Src function in osteoclasts,
but rather that the SH2 domain plays an essential role,
perhaps as an adaptor protein, in contributing to the
resorptive process [4,12]. Rescue experiments with a trun-
cated Src protein construct in which the entire kinase
domain was removed led to more severe osteopetrosis,
suggesting that the presentation of the SH2 domain as an
adaptor requires the conformation of the entire protein. 
Studies carried out with fibroblasts isolated from both
Src–/– mice and Src–/– mice expressing the kinase-dead
mutant Src construct indicate that Src SH2 domain func-
tion is particularly important for integrin receptor signaling
[35,36]. It is well established that the αvβ3 integrin recep-
tor is intimately involved in osteoclast adhesion, intracel-
lular signaling and resorption activity. Blocking αvβ3
integrin receptor binding inhibits osteoclast resorption
both in vitro and in vivo [37–39]. These findings linked
with the observations that Src is involved in regulating
αvβ3 integrin receptor signaling [40,41] lend further
insight into the process of how Src might regulate osteo-
clast-mediated resorption. They further suggest that
blocking αvß3 integrin receptor mediated intracellular
signaling, by interfering with the association of an impor-
tant regulatory protein, such as the SH2 domain of Src,
could have the potential to block osteoclast resorption.
That Src–/– mice develop a tissue-specific phenotype
restricted primarily to osteoclasts when the Src tyrosine
kinase protein is normally expressed ubiquitously suggests
that there is compensation of function by other tyrosine
kinase proteins in unaffected cell types, because of over-
lapping patterns of expression and function with other Src
tyrosine kinase members [1,2]. Such a possibility is further
supported by reports that co-disrupted expression of Src
with another member of the Src family of tyrosine kinase
proteins in mice results in more profound phenotypes and
in some cases lethality [42,43]. We suggest that selective
inhibition of osteoclast function would require either a
compound that only blocks Src activity or a nonselective
Src family inhibitor that is targeted to osteoclasts. In this
paper, we describe a compound that inhibits the binding
of the Src SH2 domain to peptide ligands using biochemi-
cal selectivity and demonstrate its utility in inhibiting Src
cellular activity and osteoclast resorption. We are working
on  a bone targeting approach to provide cellular selectiv-
ity to osteoclasts (S.M.V., et al., unpublished observations).
The structural conservation of SH2 domains in the Src
family of tyrosine kinases makes it difficult to design com-
pounds that are selective for the Src SH2 domain. The
observation that Src is the only member of the family to
contain a cysteine residue in the pTyr-binding pocket of
its SH2 domain led to the development of compounds
designed to interact specifically with this residue. The
effectiveness of 3′-formyl-pTyr-containing SH2 inhibitors
has been described [21]; these compounds have no cellu-
lar activity, however, presumably because of their phos-
phatase sensitivity and inability to effectively penetrate
cells. Similarly, we have reported [44] the synthesis of
3′-formyl-4′-phoshonodifluoromethyl-phenylalanine-con-
taining SH2 inhibitors; these compounds appear not to
engage the cysteine residue, however. A 3-formyl-
4-carboxy-substituted phenyalanine has been described as
an effective pTyr replacement, which targets Cys188 in
the phosphotyrosine-binding pocket of the Src SH2
domain [22,45]. In an abstract, it was reported that the
same molecule, in the context of a peptidic tail (EEIE-
NH2), irreversibly inhibited phosphopeptide binding to
Src SH2 domain and was effective as an antiresorptive
agent in a rat long-bone resorption assay [45]. There was
no report of selectivity of binding to the Src SH2 domain
for this compound, however. With an interest in designing
molecules that specifically target Cys188, we incorporated
3′-formyl-4′-carboxy-phenylalanine into a novel nonpep-
tide template designed to bind to the Src SH2 domain.
BIAcore binding studies were carried out with other com-
pounds from this series, preceding the synthesis of
AP22161, to determine whether they target Cys188
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(W.C.S., unpublished observations). Compounds were
tested for their ability to inhibit native Src SH2 and
mutant Cys188 Src SH2 binding to peptide ligands. These
compounds had a 100-fold lower IC50 for binding to the
native form of Src SH2 compared with the mutant Cys188
Src SH2 protein. In addition, nuclear magnetic resonance
(NMR) analyses with lead compounds demonstrated the
formation of a hemithioacetal that is dependent on the
interaction of the formyl group with Cys188 of Src SH2
(W.C.S., unpublished observations). These earlier experi-
ments clearly demonstrated that compounds with the
3-formyl-4-carboxy-substituted phenyalanine head group
target Cys188 within the Src SH2 domain. The time
course of binding was also tested with the lead series to
determine whether binding was irreversible. There was no
significant difference in binding when incubated with Src
SH2 for 0 or 36 hours, indicating that binding was
reversible. Fluorescence polarization binding assays were
carried out in parallel with the BIAcore binding studies
comparing the binding of compounds to both Src and Yes
SH2 domains. These studies confirmed that only the cys-
teine-targeted compounds selectively bound to Src SH2.
Subsequent studies with the lead series indicated that
more potent binding compounds were necessary to
achieve cellular activity. During our investigations into the
design of selective Src SH2 inhibitors, we discovered a
very effective bicyclic replacement (5) for the EEI peptide
which confers increased binding affinity (20-fold) in the
context of phosphotyrosine relative to pYEEI (W.C.S.,
unpublished observations). Moreover, this bicyclic com-
pound is nonpeptidic and, therefore, should be less sus-
ceptible to cleavage by proteolytic enzymes and
potentially more orally bioavailable. In this paper, we have
described a compound, AP22161, that contains both the
cysteine-targeted 3-formyl-4-carboxy-substituted phenyl-
alanine and the bicyclic template. We demonstrate that
AP22161 binds selectively and with high affinity to the Src
SH2 domain. We also demonstrate that this compound
inhibits Src cellular activity and osteoclast-mediated
resorption. The effects of a Src SH2 inhibitor in osteoclasts
highlight the role of the adaptor region of Src.
Significance
There is considerable interest in developing compounds
that inhibit osteoclast function as an approach to treat-
ing osteoporosis. Because the Src tyrosine kinase
protein has been implicated as an important regulator of
osteoclast resorptive activity it is believed that inhibition
of its activity could block osteoclast resorption of bone.
The highly conserved nature of Src’s SH2 and kinase
domains, which are important in regulating its cellular
functions, presents a major challenge for developing a
compound that selectively inhibits Src. Gene targeting
studies in mice suggest that selective inhibition of Src,
within the family of Src tyrosine kinases, is desirable for
developing an inhibitory compound that is not toxic to
nonosteoclast cell types. To date, most full reports of the
pharmacological approaches to inhibit Src function in
osteoclasts have been carried out with compounds that
inhibit the kinase domain of many members of the Src
family of tyrosine kinases. Although the Src SH2
domain is believed to act as an adaptor protein — impor-
tant in regulating Src interactions with downstream
targets during signal transduction — there has been no
previously reported evidence that selective inhibition of
the Src domain will inhibit Src cellular activity and
osteoclast-resorptive processes. We now describe the
synthesis and cellular effects of a compound, AP22161,
that selectively binds with high affinity to the Src SH2
domain. AP22161 was designed to be selective for the
Src SH2 domain by targeting a cysteine residue in the
highly conserved phosphotyrosine-binding pocket. This
compound was tested in various in vitro and cellular
assays and found to selectively block Src binding to its
peptide ligands, inhibit Src cellular activity and diminish
osteoclast-mediated resorption. This is the first full
description of a Src selective SH2 binding compounding
and its effects in both mechanism-based cellular assays
and osteoclast resorption studies. Such a compound pro-




PP1 was purchased from Calbiochem (San Diego, CA). cSrcY527F
transformed rat fibroblasts were developed by Adele Filson in the labo-
ratory of Joan Brugge (Harvard Medical School, Boston, MA). Two-
hybrid cell lines were constructed as previously described [32].
AP22161 synthesis
3-(1,3-Dithiolan-2-yl)-N-acetyl-L-tyrosine methyl ester. Boron tri-
fluoride diethyl etherate (0.12 ml, 0.96 mmol) was added to L-3-formyl-N-
acetyltyrosine methyl ester (2; 0.13 g, 0.48 mmol) [46] in methylene
chloride (5 ml) at 0°C followed by the addition of ethanedithiol (0.044 ml,
0.53 mmol). The mixture was then warmed to room temperature and
stirred for 1 h. The solution was mixed with water and the layers sepa-
rated. The aqueous layer was extracted with methylene chloride and the
combined extracts were washed with water, dried over magnesium
sulfate, filtered and concentrated to a solid. The solid was recrystallized
from ethyl acetate/hexane (0.14 g, 82%); melting point 97–99°C. 
3-(1,3-Dithiolan-2-yl)-4-(trifluoromethansulfonyloxy)-N-acetyl-L-
phenylalanine methyl ester (3). N-phenyltrifluoromethanesulfonimide
(0.58 g, 1.61 mmol) was added to 3-(1,3-dithiolan-2-yl)-N-acetyltyrosine
methyl ester (0.50 g, 1.46 mmol) and triethylamine (0.22 ml, 1.61 mmol)
in methylene chloride (10 ml) at 0°C. The mixture was allowed to stir for
5 days then washed sequentially with 1 N NaOH, 1 N HCl and brine.
The organic layer was dried over magnesium sulfate, filtered and con-
centrated to a solid. The solid was recrystallized from ethyl
acetate/hexane (0.61 g, 87%); melting point 116–118°C. 
3-(1,3-Dithiolan-2-yl)-4-(carboxymethyl)-N-acetyl-L-phenylala-
nine methyl ester. Triethylamine (0.33 ml, 2.36 mmol) was added to
3-(1,3-dithiolan-2-yl)-4-(trifluoromethansulfonyloxy)-N-acetyl-L-phenyl-
alanine methyl ester (3) (0.51 g, 1.08 mmol) in dimethylsulfoxide
(DMSO)/methanol (MeOH) (3:2, 5 ml) followed by the addition of pal-
ladium acetate (0.0073 g, 0.033 mmol) and 1,3-bis(diphenylphos-
phino)propane (0.013 g, 0.034 mmol). Carbon monoxide was bubbled
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through for 3 min and the mixture was heated to 80°C for 24 h. After
cooling, the solution was diluted with water and extracted with ethyl
acetate. The combined extracts were washed with water, dried over
magnesium sulfate, filtered and concentrated to a solid. The solid was
recrystallized from ethyl acetate/hexane (0.30 g, 72%); melting point
113–119°C. 
3-(1,3-Dithiolan-2-yl)-4-(carboxymethly)-N-acetyl-L-phenylala-
nine (4). Lithium hydroxide monohydrate (0.025 g, 0.60 mmol, 1 ml
water) was added to 3-(1,3-dithiolan-2-yl)-4-(carboxymethyl)-N-acetyl-L-
phenylalanine methyl ester (0.22 g, 0.57 mmol) in tetrahydrofurane
(THF, 10 ml) at 0°C. The mixture was stirred for 45 min, diluted with
water, made acidic with 1 N HCl, and extracted with ethyl acetate. The
combined extracts were washed with water, dried over magnesium
sulfate, filtered and concentrated to a glassy solid, which was homoge-
neous by reverse-phase high-pressure liquid chromatography (HPLC,
0.18 g, 86%). Mass spectrometry [M–H]– 368. 
4-[(S)-2-Acetylamino-2-(3-carbamoyl-2-cyclohexylmethoxy-
6,7,8,9-tetrahydro-5H-benzocyclohepten-(R,S)-5-ylcarbamoyl)-
ethyl]-2-[1,3]dithiolan-2-yl-benzoic acid methyl ester. 1-Hydrox-
ybenzotriazole (0.051 g, 0.35 mmol) and 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (0.072 g, 0.35 mmol) was added
to 3-(1,3-dithiolan-2-yl)-4-(carboxymethyl)-N-acetyl-L-phenylalanine (4)
(0.13 g, 0.35 mmol) in CH2Cl2/dimethylformamide (5:1, 5 ml) at 0°C.
The mixture was stirred for 10 min and then (R,S )-9-amino-3-cyclo-
hexylmethoxy-6,7,8,9-tetrahydro-5H-benzocycloheptene-2-carboxylic acid
amide (5) (0.10 g, 0.32 mmol) (W.C.S., unpublished observations) was
added and stirring was continued for 1 h. The solution was added to
water and the layers separated. The aqueous layer was extracted with
methylene chloride and the combined extracts were washed with
water, 1 N HCl, dried over magnesium sulfate, filtered and concen-
trated to a glassy solid (0.20 g, 99%), which was homogeneous by
reverse-phase HPLC. Mass spectrometry [M–H]– 636.
4-[(S)-2-Acetylamino-2-(3-carbamoyl-2-cyclohexylmethoxy-
6,7,8,9-tetrahydro-5H-benzocyclohepten-(R,S)-5-ylcarbamoyl)
-ethyl]-2-formyl-benzoic acid methyl ester. Mercury (II) perchlo-
rate hydrate (0.38 g, 0.94 mmol) was added to 4-[(S)-2-acetylamino-2-
(3-carbamoyl-2-cyclohexylmethoxy-6,7,8,9-tetrahydro-5H-benzocyclohep
ten-(R,S)-5-ylcarbamoyl)-ethyl]-2-[1,3]dithiolan-2-yl-benzoic acid methyl
ester (0.20 g, 0.31 mmol) in CHCl3/MeOH (1:1, 6 ml). The mixture was
stirred for 5 min and then filtered though Celite (CHCl3 wash). The
organic layer was washed with 1 N HCl, saturated NaHCO3, dried over
magnesium sulfate, filtered and concentrated to a glassy solid (0.18 g),
which was used immediately in the next reaction.
4-[(S)-2-Acetylamino-2-(3-carbamoyl-2-cyclohexylmethoxy-
6,7,8,9-tetrahydro-5H-benzocyclohepten-(S)-5-ylcarbamoyl)-
ethyl]-2-formyl-benzoic acid (1). Lithium hydroxide monohydrate
(0.018 g, 0.42 mmol, 1 ml water) was added to 4-[(S)-2-acetylamino-2-
(3-carbamoyl-2-cyclohexylmethoxy-6,7,8,9-tetrahydro-5H-benzocyclo-
hepten-(R,S)-5-ylcarbamoyl)-ethyl]-2-formyl-benzoic acid methyl ester
(0.18 g, 0.32 mmol) in THF (5 ml). The mixture was stirred for 1 h, acid-
ified with trifluoroacetic acid and evaporated. The residue was diluted
with DMSO (2 ml) and purified by reverse-phase HPLC (CH3CN/H2O).
Lyophilization left a white solid (0.040 mg, 21%). 1H NMR (300MHz,
DMSO) indicates a 4:1 mixture of hemiacetal (HA)/aldehyde (Ald.)
δ 0.96–1.38 (m, 7H), 1.60–1.80 (m, 7H), 2.81 (dd, J = 12.2, 10.1 Hz,
1H), 2.96 (m, 1H), 2.56 (d, J = 5.7 Hz, 2H), 4.52 (m, 1H), 4.79 (m,
1H), 6.41 (s, 40% HA), 6.50 (s, 40% HA), 6.89 (dd, J = 8.6, 4.0 Hz,
1H), 7.13 (br d, J = 9.1 Hz, 1H), 7.39 (m, 4H), 7.59 (m, 1H), 7.69 (s,
1H), 7.96 (br s, 1H), 8.41 (br s, 1 H), 10.38 (s, 20% Ald.). Mass spec-
trometry [M–H]– 576.
Proteins for binding assay
Human Src SH2 domain protein (residues Ser145–Ser251) and human
tandem ZAP SH2 domain protein (residues Met1–Ala259) were pro-
duced and purified as described previously [29,47]. Murine Yes SH2
domain protein (residues Ser150–Val256) is identical to human Yes SH2
in sequence except that Val202 in the murine protein is Ile204 in the
human protein. This residue is in the CD loop far removed from the
binding site and the sequence difference is therefore not expected to
affect binding. Murine Yes SH2 was expressed from vector pT7.7 in
E. coli BL21 (DE3) cells grown in BHI medium containing 200 mg/l ampi-
cillin and induced with 1 mM isopropyl β-D-thiogalactopyranoside (IPTG)
for 4 h at 30°C. The cells were resuspended in two volumes of 75 mM
Tris/Tris–HCl pH 7.0, containing 300 mM NaCl, 7.5 mM dithiothreitol
(DTT), 7.5 mM ethylenediaminetetraacetic acid (EDTA), 1.5 mM phenyl-
methylsulfonyl fluoride (PMSF), and lysed using a French pressure cell at
16,000 psi. The lysate was diluted twofold with 50 mM Tris/Tris-HCl
pH 7.0, 5 mM DTT, 2 mM EDTA, 1 mM PMSF and clarified by filtration
and centrifugation at 20,000 g for 30 min. The clarified lysate was diluted
3.5-fold with H2O, adjusted to pH 7.0, and purified over carboxy-sulfon
(J.T. Baker, Phillipsburg, NJ) a weak-strong cation exchanger, equilibrated
with 20 mM Tris/Tris-HCl, 5 mM DTT, 0.02% NaN3, pH 7.0. The Yes
SH2 protein was eluted with a 2M NaCl gradient. The protein was then
purified by gel filtration on a 2.6 × 94 cm Sephacryl S-100 (Pharmacia,
Uppsala, Sweden) column equilibrated with 20 mM BES, 200 mM NaCl,
5 mM DTT, 0.02% NaN3, pH 7.0. Gel filtration was essential for removal
of a variable fraction of domain-swapped dimers. Purity of the final protein,
as measured by sodium dodecylsulfate (SDS) gel electrophoresis was
> 95% and the protein was 97% monomer. Once the monomer was iso-
lated, little or no dimer was formed on storage in the S100 buffer at
1.3 mg/ml for up to 1 week at 4°C and several hours at room tempera-
ture. The monomer was also stable to multiple freeze-thaws. 
Fluorescence polarization binding assay
Details of the fluorescence polarization method to monitor ligand
binding to Src SH2 and tandem ZAP SH2 have been described previ-
ously [29,47]. The fluorescein-conjugated peptide used to monitor Src
SH2 and Yes SH2 binding was fluorescein-pYpYpYIE-NH2 and the
probe used to monitor ZAP tandem SH2 binding was fluorescein-
GpYNELNLGRREEpYDVL-NH2 [47]. The Yes SH2 binding pocket is
very similar to Src SH2 except that Cys188 of human Src is Ser193 of
murine Yes. Yes SH2 was therefore assayed with the same probe as
Src SH2. By performing a complete saturation binding curve with a
fixed concentration of peptide probe and increasing concentrations of
SH2 protein, the Kd of the peptide probe–SH2 protein interaction was
determined. Yes SH2 was found to have an ~twofold higher affinity
than Src SH2 for the probe, which required use of a somewhat lower
protein concentration in the compound inhibition assays (90 nM instead
of 150 nM as for Src SH2). For compound inhibition assays, serial
twofold dilutions of compounds in buffer solution (20 mM phosphate
buffer pH 7.4, containing 100 mM NaCl, 10 mM DTT, 2% DMSO,
1 mM EDTA, and 0.1% gamma globulin) were tested. Compounds
(0.04–500 µM) were then added to a constant concentration of SH2
protein premixed with 20 nM of the corresponding fluorescein-conju-
gated peptide. The protein concentrations used were 25 nM for tandem
ZAP SH2, 90 nM for Yes SH2, and 150 nM for Src SH2. Binding reac-
tions were carried out for 5 min at room temperature. Fluorescence
polarization of the samples was measured on a Jolly FPM2 96-well plate
reader with standard cutoff filters (excitation λ = 485 nm, BP = 22;
emission λ = 530 nm, BP = 30). The 50% inhibitory concentration of
each compound (IC50) was calculated based on the % binding of the
fluorescein-conjugated peptide to SH2 protein in the presence of com-
pound relative to vehicle alone control samples. Results are shown from
three or more experiments each containing triplicate samples.
Mammalian two-hybrid assay
Cells were cultured in minimal essential medium eagle (Cellgro,
Herndon, VA) supplemented with 10% heat inactivated fetal bovine
serum (HIFBS, Hyclone, Logan, UT), 0.5 mg/ml active G418 (Gibco-
BRL, Grand Island, NY), 50 units/ml penicillin, 0.05 mg/ml strepto-
mycin, 2 mM glutamine, 50 µg/ml hygromycin, and 0.1 mM MEM
nonessential amino acids (Gibco-BRL). Cells were plated into 96-well
plates at 20,000 cells per well and incubated for 4 h at 37°C and 5%
CO2. Fresh culture medium containing serially diluted test compounds
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was added to cells and incubated for 3 h at 37°C in 5% CO2, and then
estrogen was added to a final concentration of 1 µM. Cells were incu-
bated with test compounds and estrogen for 16 h at 37°C and 5%
CO2. After incubation, supernatant was collected and transferred into
96-well plates to examine SEAP activity and the remaining cells were
monitored for alamar reactivity or [3H]-uridine incorporation to assess
non-specific toxic effects of compounds. Results are shown as the
mean percent of control ± S.E.M. from at least three independent
experiments each containing triplicate samples.
SEAP activity
Supernatant transferred to 96-well plates was incubated for 90 min at
65°C to inactivate nonspecific phosphatase activity. 100 µl of heat
inactivated supernatant was transferred into 96-well fluorometer plates
(Perkin Elmer, Norwalk, CT) followed by the addition of 100 µl 2 M
diethanolamine, and 1.32 mM 4-methylumbelliferylphosphate. Plates
were covered and incubated in a humidified incubator at 37°C. Fluo-
rescence was measured on an LS 50 B Perkin Elmer Luminescence
Spectrometer using 350 nM excitation and 445 nM emission.
Alamar reactivity
After culture media was removed for SEAP analysis 200 µl of fresh
culture media containing 10% alamar Blue (Alamar Biosciences Inc.,
Sacramento, CA) was added to each well and incubated for 2–3 h at
37°C and 5% CO2. Absorbance was measured at 570 nM. 
Treatment of cSrc ∆ 527 transformed cells
Cells were plated into 12-well plates at 5 × 104 cells/well in 1.0 ml dul-
becco’s modified eagle medium (Gibco-BRL) supplemented with 10%
HIFBS (Hyclone), 50 units/ml penicillin, 0.05 mg/ml streptomycin, and
2 mM glutamine and incubated overnight at 37°C in 5% CO2. The next
day medium was replaced with fresh culture medium supplemented
with test compounds. Cells were refed with fresh medium containing
compounds every other day. Cells were counted on days 2, 3, 4, 5 and
7. The effects of compounds on morphological reversion was deter-
mined after 4 days of exposure. Data are shown as the mean number of
cells counted ± S.E.M. from four separate samples.
Resorption assay
Femurs, tibias and scapulas were isolated from 3–4 day old New
Zealand white rabbits. Bones were chopped and minced in minium
essential medium alpha (Gibco-BRL) containing 0.55 g/l NaHCO3,
10 mM HEPES (Gibco-BRL), 50 units/ml penicillin, and 0.05 mg/ml
streptomycin, pH 7.1. Bone fragments were allowed to settle, super-
natant was collected and centrifuged at 400 RPM (Beckman GS-6KR)
for two minutes, and the cell pellet was resuspended in the same
medium supplemented with 10% HIFBS (Hyclone). 0.75 ml of cell sus-
pension was added on top of dentine slices in 24-well plates that were
preincubated for 4 h at 37°C with 0.75 ml culture medium. Osteoclasts
were allowed to adhere for 30 min at 37°C and 5% CO2 and then the
medium and nonadherent cells and debris were removed by aspiration.
Fresh culture medium containing serially diluted test compounds was
added. Cells were incubated on dentine with or without compound for
24 h at 37°C and 5% CO2. After the resorption phase, dentine slices
were soaked for 30 s in 0.5% sodium hypochlorite, wiped clean of
adherent cells, and then stained for 30–45 s with 1% toluidine blue.
Sperm whale dentine was cut into 1 mm × 6 mm circular discs. Resorp-
tion was measured using reflective light microscopy and automated
image analysis. The resorbed area was measured on the entire 6 mm
disc. Remaining cells in the 24-well plates were stained for TRAP and
also assessed visually for the presence of fibroblasts. Experiments
were carried out containing triplicate samples for each concentration of
compound with five untreated control samples per plate. Results are
reported as mean percent of control resorption ± the S.E.M. from three
independent experiments each containing triplicate samples.
TRAP staining
Cell culture wells were washed one time with phosphate buffered
saline (PBS), fixed with 3.7% formaldehyde for 5 minutes at room
temperature, and then incubated with acetone:ethanol (1:1) for 30 s.
Cells were stained with 0.5 ml per well of TRAP staining solution
[0.24 mM Napthol-AS-MX phosphate sodium salt (Sigma, St. Louis,
MO), 0.14 mM N,N-dimethyl formamide (Sigma), 1.6 mM fast red
violet LB salt (Sigma), 40 mM anhydrous sodium acetate (Sigma), and
10 mM sodium tartrate (Sigma)] for 5 min. After staining the solution
was aspirated and replaced with 0.5 ml PBS. 
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